www.fdanews.com/articles/70125-genta-receives-orphan-drug-designation-for-leukemia-candidate
Genta Receives Orphan-Drug Designation for Leukemia Candidate
March 22, 2005
The FDA has granted orphan-drug designation to Genta for its drug candidate LR3001, a compound intended to treat chronic myelocytic leukemia.
The drug has already been tested in two Phase I clinical trials in patients with myeloid leukemia, and Genta said it plans to pursue further clinical development of the compound in patients with both hematologic cancers and solid tumors.